{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:04:10Z","timestamp":1761501850741,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":369,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ymthe.2021.04.012","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T15:55:12Z","timestamp":1619106912000},"page":"1659-1660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["AAV-CNS matters turn from gray to white"],"prefix":"10.1016","volume":"29","author":[{"given":"Aaron","family":"Mitchell-Dick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aravind","family":"Asokan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2021.04.012_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","article-title":"Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality","volume":"101","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.04.012_bib2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaneurol.2018.0233","article-title":"Adeno-Associated Viral Vector (Serotype 2)\u2013Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial","volume":"75","author":"Rafii","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ymthe.2021.04.012_bib3","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrd.2018.110","article-title":"Gene therapy for neurological disorders: progress and prospects","volume":"17","author":"Deverman","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2021.04.012_bib4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/hum.2019.367","article-title":"Postmortem Analysis in a Clinical Trial of AAV2-NGF Gene Therapy for Alzheimer\u2019s Disease Identifies a Need for Improved Vector Delivery","volume":"31","author":"Castle","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2021.04.012_bib5","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.ymthe.2021.01.026","article-title":"Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease","volume":"29","author":"Heller","year":"2021","journal-title":"Mol Ther."},{"key":"10.1016\/j.ymthe.2021.04.012_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/mgme.2000.2990","article-title":"Krabbe Disease: Genetic Aspects and Progress toward Therapy","volume":"70","author":"Wenger","year":"2000","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2021.04.012_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ymthe.2018.01.009","article-title":"Long-Term Improvement of Neurological Signs and Metabolic Dysfunction in a Mouse Model of Krabbe Disease after Global Gene Therapy","volume":"26","author":"Marshall","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2021.04.012_bib8","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1002\/jnr.23882","article-title":"Intrathecal administration of AAV\/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant","volume":"94","author":"Karumuthil-Melethil","year":"2016","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.ymthe.2021.04.012_bib9","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/mt.2015.145","article-title":"Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice","volume":"23","author":"Rafi","year":"2015","journal-title":"Mol Ther."},{"key":"10.1016\/j.ymthe.2021.04.012_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ymgme.2014.12.300","article-title":"Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features","volume":"114","author":"Rafi","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2021.04.012_bib11","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1523\/JNEUROSCI.4303-11.2012","article-title":"Self-renewal and differentiation of reactive astrocyte-derived neural stem\/progenitor cells isolated from the cortical peri-infarct area after stroke","volume":"32","author":"Shimada","year":"2012","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2021.04.012_bib12","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.neuron.2011.05.013","article-title":"NG2-glia as multipotent neural stem cells: fact or fantasy?","volume":"70","author":"Richardson","year":"2011","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2021.04.012_bib13","doi-asserted-by":"crossref","first-page":"1252304","DOI":"10.1126\/science.1252304","article-title":"Neuronal Activity Promotes Oligodendrogenesis and Adaptive Myelination in the Mammalian Brain","volume":"344","author":"Gibson","year":"2014","journal-title":"Science"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621001994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001621001994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:00:16Z","timestamp":1761501616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001621001994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1525001621001994"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.012","relation":{},"ISSN":["1525-0016"],"issn-type":[{"type":"print","value":"1525-0016"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV-CNS matters turn from gray to white","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}